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Background: Chronic exposure to low cadmium (Cd) levels produces urinary excretion of low molecular weight
proteins, which is considered the critical effect of Cd exposure. However, the mechanisms involved in Cd-induced
proteinuria are not entirely clear. Therefore, the present study was designed to evaluate the possible role of
megalin and cubilin (important endocytic receptors in proximal tubule cells) and angiotensin II type 1 (AT1)
receptor on Cd-induced microalbuminuria.
Methods: Four groups of female Wistar rats were studied. Control (CT) group, vehicle-treated rats; LOS group, rats
treated with losartan (an AT1 antagonist) from weeks 5 to 8 (10 mg/kg/day by gavage); Cd group, rats
subchronically exposed to Cd (3 mg/kg/day by gavage) during 8 weeks, and Cd + LOS group, rats treated with
Cd for 8 weeks and LOS from weeks 5–8. Kidney Cd content, glomerular function (evaluated by creatinine clearance
and plasma creatinine), kidney injury and tubular function (evaluated by Kim-1 expression, urinary excretion of
N-acetyl-β-D-glucosaminidase (NAG) and glucose, and microalbuminuria), oxidative stress (measured by lipid
peroxidation and NAD(P)H oxidase activity), mRNA levels of megalin, expressions of megalin and cubilin
(by confocal microscopy) and AT1 receptor (by Western blot), were measured in the different experimental groups.
Data were analyzed by one-way ANOVA or Kruskal-Wallis test using GraphPad Prism 5 software (Version 5.00).
P < 0.05 was considered statistically significant.
Results: Administration of Cd (Cd and Cd + LOS groups) increased renal Cd content. LOS-treatment decreased
Cd-induced microalbuminuria without changes in: plasma creatinine, creatinine clearance, urinary NAG and glucose,
oxidative stress, mRNA levels of megalin and cubilin, neither protein expression of megalin nor AT1 receptor, in the
different experimental groups studied. However, Cd exposure did induce the expression of the tubular injury
marker Kim-1 and decreased cubilin protein levels in proximal tubule cells whereas LOS-treatment restored cubilin
levels and suppressed Kim-1 expression.
Conclusion: LOS treatment decreased microalbuminuria induced by Cd apparently through a cubilin
receptor-dependent mechanism but independent of megalin.
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Cadmium (Cd) is a heavy metal found in the earth’s
crust associated with lead, zinc and copper. Currently,
this metal has become an environmental and public
health problem due to its constant release by industrial
activity. However, Cd is used for the manufacture of bat-
teries, pigments, consumer electronics, and quantum
dots [1,2]. This metal enters the food chain through con-
taminated air, water, and soils where it is caught and
fixed by plants (ie. sunflower kernels and rice), molluscs
and crustaceans (Cd contents >1-2 mg/kg ww) [3-5]. In
consequence, general population is exposed to Cd by
contaminated water and food [4,6]. Another important
source of Cd is cigarette smoke at a concentrations of
1–2 μg Cd per cigarette. Smokers have more Cd in
blood and kidneys than non-smokers. Smoking a pack of
cigarettes per day leads to an absorption of 1–3 μg of
Cd [1,4,7]. The kidney is the main organ affected by
chronic Cd exposure. Ninety percent of filtered Cd is
reabsorbed in the proximal tubule particularly in the S1
and S2 segments [8,9]. It has been reported that Cd enters
proximal tubular cells by different routes: endocytosis
(Cd conjugated with metallothionein or low molecular
thiols) and transporters such as zinc transporter 1(ZnT1),
ATP-binding cassette protein (ABC protein; located at
basolateral membrane), ZrT/Irt-like protein (ZIP), Diva-
lent Metal Transporter 1 (DMT1), and Na+-amino acid
co-transporters [9,10]. Inside the cell, Cd induces proteins
such as metallothionein 1/2 (MT1/2) and interacts with
their sulfhydryl groups, altering protein function [11,12].
Main nephrotoxic symptoms of Cd exposure are protein-
uria, glycosuria, aminoaciduria, and phosphaturia similar
to Fanconi’s syndrome [11,13]. The Agency for Toxic Sub-
stances and Disease Registry (ATSDR) has determined a
dose of 0.1 μg Cd/kg/day as Minimal Risk level (MRL)
based on low molecular weight proteinuria (LWP) during
a chronic-oral exposure [1]. Different studies have been
designed to elucidate the mechanisms by which Cd in-
duces proteinuria [14-16]. However, it has been reported
that Cd toxicity depends on dose, route of administration
and time of exposure. The glomerulus retains large pro-
teins (>67 kDa), but low weight proteins pass freely
through the glomerular barrier and are reabsorbed along
the proximal tubule. Normally, a healthy adult excretes
from 40 to 80 mg of protein per day, from which 10 to
15 mg is albumin [17,18]. Filtrated albumin is reabsorbed
in the proximal tubule; therefore albuminuria may result
from an over-filtration of plasma proteins, glomerular or
tubular dysfunction [17,19,20]. Protein reabsorption at the
proximal tubule is accomplished by receptor-mediated
endocytosis. Two receptors responsible for endocytosis,
megalin and cubilin, have been described as major players
in this phenomena [21,22]. Megalin is a glycoprotein of
600 KDa, member of the low-density lipoprotein receptor(LDLR) family. Megalin is a multiligand receptor with a
large NH2-terminal extracellular domain rich in cysteine,
a single transmembrane domain and a COOH-terminal
short cytoplasmic domain with NPXY motifs that are re-
sponsible for internalization mediated by clathrin [22-24].
On the other hand, cubilin is a peripheral membrane
protein of 460 KDa, without transmembrane and cytoplas-
mic domains; cubilin contains 27 COOH-terminal CUB
domains (complement subcomponents C1r/C1s, Uegf)
which are ligand binding. Cubilin has different ligands,
including megalin. In the proximal tubule cells, cubilin is
co-expressed with megalin, and interacts with it, forming
a complex to be internalized [25]. A decrease in the ex-
pression of megalin receptor favors the presence of pro-
teins into urine (as captesin B, RPB and albumin) [21] and
cubilin deficiency leads to an increase in albumin excre-
tion [26]. Endocytosis along the proximal tubule is regu-
lated by different factors, including angiotensin II (Ang II),
an active vasopeptide of the renin-angiotensin system
(RAS). RAS is an hormonal system that begins with renin
secretion; this enzyme acts upon its substrate angio-
tensinogen, resulting in the formation of angiotensin I
(Ang I) which in turn is hydrolyzed and converted to Ang
II by the angiotensin converting enzyme (ACE) [27,28]. It
has been suggested that Ang II can downregulate megalin
and the treatment with RAS inhibitors or AT1 receptor
blockers decreases proteinuria and protects kidney func-
tion independent of the effect of drugs on blood pressure
[29,30]. In diabetic rats the infusion of Ang II decreases
megalin expression and albumin reabsorption, but AT1 re-
ceptor blockers may restore this effect [31]. Hosojima
et al. (2009) proposed that Ang II negatively regulates
megalin expression at both mRNA and proteins levels,
through the AT1 receptor and ERK pathway activation
[32]. On the other hand, there is evidence that the RAS is
implicated in the toxicity of cadmium [33-35]. In the
present study, we evaluated the role of the megalin-cubilin
complex and AT1 receptor on tubular endocytosis of albu-
min during a subchronic exposure to Cd in rats.
Methods
Animals and treatment
Female Wistar rats (180–220 g bw) were used. Animals
were housed with 12/12-h light/dark cycles at 22 ± 1°C,
50 ± 5% humidity and received standard chow (PMI,
5008, Purina, Alief City, TX) and purified water ad
libitum. The use of animals was in accordance with the
Institute for Laboratory Animal Research (ILAR) Guide
for Care and Use of Laboratory Animals and was
approved by the Institutional Ethical Committee at
Cinvestav, CICUAL [Comité Interno para el Cuidado y
Uso de los Animales de Laboratorio; Number 391–07].
Rats were divided into four groups: 1) Control (CT):
rats were administered with water by gavage for eight
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administered with Losartan, an AT1 antagonist (Cozaar,
50 mg, Merck Sharp and Dohme de México S.A. de
C.V.) (10 mg/kg/day, by gavage). 3) Cd: rats were admin-
istered with cadmium chloride (CAS No. 10108-64-2,
Sigma Aldrich) (3 mg/kg/day, by gavage) for 8 weeks
(weeks 0–8). 4) Cd + LOS: rats were administered
with Cd for 8 weeks and LOS from weeks 5 to 8. One
day after the end of treatment, rats were housed
individually in metabolic cages to collect 16 h urine
for the measurements of microalbuminuria, creatinine,
N-acetyl-β-D-glucosaminidase (NAG) and glucose. After
urine collection, animals were sacrificed with an over-
dose of Nembutal (pentobarbital sodium, 50 mg/100 g
bw, i.p.). The kidneys were removed and washed in cold
PBS. A half of the right kidney was used to determine
cadmium content and a second half was used to ex-
tract RNA for RT-PCR. A half of the left kidney was
frozen at −70°C using 2-methylbutane as cryoprotec-
tor for immunofluorescence assays and a second half
was used to extract proteins for Western blot and
oxidative stress measurements.
Urine and plasma measurements
Urine samples were centrifuged for 10 min at 1000 × g,
and aliquots were separated. Blood samples were
obtained by cardiac puncture and centrifuged for 15 min
at 2000 × g to obtain plasma. Creatinine was measured
in plasma and urine using the Jaffé method (CR510,
Randox Laboratories, San Diego, CA) and glucose was
measured in urine by the hexokinase method (GL161,
Randox Laboratories, San Diego, CA). Microalbuminuria
was measured using the HemoCue Albumin 201 system.
Urinary NAG was determined at 580 nm by using a col-
orimetric assay (Cat. No. 875 406; Roche diagnostic).
Creatinine clearance was calculated using the standard
equation
Ccr ¼ Ucr=Pcrð ÞxJv
where Ccr is the value of creatinine clearance (μL/min/
100 g bw), Ucr, and Pcr are the concentration values
(mg/dL) of creatinine in urine and plasma, respectively,
and Jv is the urinary flow rate (μL/min/100 g bw).
Measurement of renal cadmium content
The technique used to quantify Cd content was described
previously by the Environmental Protection Agency (EPA)
[36]. Kidney samples were weighed and digested in a solu-
tion (2:1) of nitric acid (9601–02, Reactive Grade, J.T.
Baker, 69.9% of purity) and hydrochloric acid (9535–02,
Reactive Grade, J.T. Baker, 37.1% of purity) plus 3 mL of
hydrogen peroxide (2186, Reactive Grade, J.T. Baker, 30%
of purity) overnight. Afterwards, samples were heated to atemperature of 80-90°C until full organic matter digestion
was observed by the release of nitrous fumes (yellow-or-
ange). In order to remove any organic residue, 3 mL of
hydrogen peroxide were added to samples for 5 min, leav-
ing the mixture to react at 80-90°C until the solution
turned transparent. At the end of this period, the solution
was filtered and diluted to 10 mL with deionized water. In
the final solution, Cd concentration was quantified by a
standard curve using atomic absorption direct aspiration
flame (Perkin Elmer, AAnalyst 100), with detection limit
of 0.008 mg/L. The following calculation was performed
to express the concentration in mg/g tissue:
Cd mg=gð Þ ¼ Cd mg=Lð Þ½   Volumeof dilution Lð Þ
=weightof sample gð Þ
Lipid peroxidation determination
Renal cortex was homogenized in phosphate buffer
(50 mM, pH 7.4) containing 10 μL of butylated hydroxy-
toluene (0.5 M) in acetonitrile. Subsequently, the hom-
ogenate was centrifuged for 10 min (3000 x g at 4°C).
Protein concentrations of the supernatants were deter-
mined using the Lowry assay. The supernatants were
mixed with a solution (1:3) of 1-methyl-2-phenylindole
in a mixture of acetonitrile methanol (3:1), reactions
were started adding 37% HCl. Later, samples were incu-
bated for 40 min at 40°C. Lipid peroxidation was evalu-
ated by measuring 4-hydroxynonenal (4-HNE) and
malondialdehyde (MDA) using a standard curve of tetra-
methoxypropane at 586 nm [37,38].NAD(P)H oxidase activity determination
Renal cortex was homogenized in phosphate buffer
(50 mM, pH 7.4; w/v 1:10), containing 1 mM EDTA, 0.1%
triton-X100 and protease inhibitors. Subsequently the
homogenate was centrifuged for 10 min (6000 x g at 4°C).
Supernatants were incubated with 0.02 mM dihydro-
ethidium (DHE), 0.05 mg/ml salmon testes DNA, and the
corresponding substrate for NAD(P)H oxidase in a dark
plate away from direct light and at 37°C for 30 min. DHE
is oxidized to ethidium (Eth) and is used as a marker of
superoxide (O2
•¯) formation. Eth-DNA fluorescence was
measured at an excitation wavelength of 480 nm and an
emission of 610 nm by using a fluorescence multimode
microplate reader (Synergy HT; Biotek) [39]. 0.1 mM of
NADH was used as a substrate in the reaction mixture. To
further confirm that the activity of NAD(P)H oxidase con-
tributes to the production of O2
•¯; diphenylene iodonium
(DPI, 0.1 mM) a NAD(P)H oxidase inhibitor, was used. The
fluorescent signal of each sample was expressed as DHE
fluorescence relative to the control. Protein concentrations of
the supernatants were determined using the Lowry assay.
Table 1 List of primers used for megalin gene
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Kidneys were sectioned in a Leica CM1100 cryostat
(sections of 8 μm) and the slices were transferred on
gelatin-coated slides. The slices were fixed for 10 min
with methanol at −20°C; thereafter the slices were
washed with PBS (with 1 mM calcium) and then perme-
abilized with 0.2% Triton-X100 for 5 min at room
temperature, and afterwards, washed twice with PBS.
After the blocking them for 1 h at room temperature
with 1% (w/v) IgG-free-albumin, the slices were incu-
bated overnight at 4°C with primary polyclonal goat
anti-megalin antibody (sc-16478, Santa Cruz Biotech-
nology, Inc., dilution 1:50), polyclonal goat anti-cubilin
antibody (sc-20609, Santa Cruz Biotechnology, Inc., di-
lution 1:50), polyclonal goat anti Kim-1 antibody (Cat.
No. AF3689, R&D System, dilution 1:500) or monoclo-
nal mouse anti-dipeptidyl-peptidase (IV) antibody
(MCA924, Serotec Ltd., Kidlington, Oxford, OK, dilu-
tion 1:500 ). After three washes for 5 min with PBS at
room temperature, the secondary antibody Alexa-Fluor
594 donkey anti goat (A11058, Invitrogen, dilution
1:300), Alexa-Fluor 488 donkey anti goat (A11055,
Invitrogen, dilution 1:500) or Alexa-Fluor 594 donkey
anti mouse (A21203, Invitrogen, dilution 1:500) was
added for 2 h at room temperature. Later, the slices
were washed three times with PBS, and mounted with
Vectashield H-1400 (Vector laboratories Inc. Burlin-
game, CA). The immunofluorescence was examined
using a multiphotonic confocal microscope (Leica
TCSSP5 MO PANDEM) and analyzed with Leica
Microsystem LAS AF Lite software. Megalin and cubilin
fluorescence intensity was quantified in three images
from three different rats per group.
Western-blot
The renal cortex was homogenized in cold buffer A
(250 mM sucrose, 5 mM EDTA, 10 mM HEPES, prote-
ase inhibitors at pH 7.8), and then centrifuged at 4°C for
15 min 13000 x g, the pellet was resuspended on ice
cold buffer B (2 mM CaCl2, 1 mM MgCl2, 10 mM
HEPES, 140 mM NaCl, protease inhibitors, and 1% Tri-
ton X-100 at pH 7.8). Afterwards, the samples were
centrifuged at 4°C for 30 min at 13000 x g. Protein con-
centrations of the supernatants were determined using
Pierce BCA protein assay (No. 23225, Thermo Scien-
tific). The supernatants were electrophoresed on 12%
SDS-PAGE polyacrylamide and the proteins were trans-
ferred to nitrocellulose membranes (Bio-Rad Laborator-
ies). Membranes were blocked for 1 h with 5% low-fat
dry milk, next the blots were incubated with primary
rabbit anti-AT1 antibody (sc-579, Santa Cruz Biotech-
nology, Inc.), diluted 1:200 in 10 mM PBS (Cat. No.
21300–058, Gibco by Life Technologies) containing 0.1%
tween overnight at 4°C. Blots were washed three timesfor 10 min in 10 mM PBS containing 0.1% tween and in-
cubated for 1 h with the secondary antibody (goat anti-
rabbit IgG 1:10000, sc-2004 Santa Cruz Biotechnology,
Inc.) at room temperature. After three washes for
10 min in 10 mM PBS containing 0.1% tween, the pro-
teins were detected by a chemiluminescence assay (RPN
2109, Amersham).
Real-time PCR
The RNA was extracted withTrizol protocol, using 100 mg
of renal cortex; and the cDNA was synthetized with the
ImProm-II Reverse Transcription system (A3800, Promega
Corporation). The megalin and cubilin genes were analyzed
by quantitative RT-PCR using the TaqMan system in a
7500 real time PCR system (Applied Biosystems). Fluores-
cence for each cycle was analyzed quantitatively, and gene
expression was normalized for the expression of the house-
keeping gene GAPDH (Part Number 4352338E, Applied
Biosystems). The forward and reverse primers for megalin
are listed in Table 1, and for the cubilin gene, a commercial
TaqMan gene expression assay was used (Part Number
4331182, Applied Biosystems).
Statistical analyses
Data were analyzed by one-way ANOVA or Kruskal-
Wallis test using GraphPad Prims 5 software (Version
5.00). KS normality test and Bonferroni’s or Dunn’s poshoc
test were used. P < 0.05 was considered statistically signifi-
cant. The data are expressed as means ± SEM.
Results
Effect of Cd on body weight, water intake and renal
content
The first aim of this study was to explore the effect of
Cd treatment on physiological parameters such as body
weight, water intake and renal accumulation of this
metal on the different treated groups at the end of the
exposure period. Table 2 shows, no alterations on body
weight in the different experimental groups. Interest-
ingly, Cd + LOS group showed a significant increase in
water intake (approximately 2-fold) when compared with
CT, LOS and Cd groups.
As expected, gavage administration of Cd increased
renal Cd content, which was significant in both, Cd and
Cd + LOS groups (7.6 μg/g kidney) compared to CT and
LOS groups (0.087 μg/g kidney) (Table 2).
Table 2 Effect of subchronic exposure to cadmium on
body weight, water intake and renal cadmium content
Experimental
group
CT LOS Cd Cd + LOS
Body weight (g) 263 ± 19 256 ± 22 263 ± 21 256 ± 17
Water intake
(ml/100 g/16 h)
8.33 ± 2.94 11.38 ± 6.33 10.20 ± 3.84 20.20 ± 13.75a,b,c
Renal Cd levels
(μg/g wet tissue)
0.08 ± 0.00 0.08 ± 0.00 7.6 ± 1.12d,e 7.6 ± 0.97d,e
LOS, losartan. Data represent the means ± SEM, n = 9–10. aP < 0.05 vs CT, bP <
0.05 vs LOS, cP < 0.05 vs Cd, dP < 0.001 vs CT, eP < 0.001 vs LOS.
Santoyo-Sánchez et al. BMC Nephrology 2013, 14:211 Page 5 of 12
http://www.biomedcentral.com/1471-2369/14/211Effect of Cd on urinary flow rate, plasma creatinine and
creatinine clearance
To determine whether Cd alters renal function in our
experimental conditions, we measured urinary flow rate
(Jv) and estimated glomerular filtration rate (eGFR) de-
termined by creatinine clearance (Figure 1).
Rats treated with Cd + LOS showed increased urinary
flow rate compared with CT (p < 0.05), LOS (p < 0.05),
and Cd (p < 0.05) groups (Figure 1A). Meanwhile, no
changes were found in plasma creatinine and creatinine
clearance in the different treated groups (Figure1B and C)
our results indicate that none of the treatments affected
glomerular function.
Effect of Cd on urinary glucose concentration, urinary
NAG, microalbuminuria and Kim-1 expression
In order to explore proximal tubular function, urinary con-
centrations of glucose, and NAG, and microalbuminuria
were determined (Figure 2).
No changes were found in urinary excretion of glucose
and NAG in the different treated groups. However,
microalbuminuria was significantly increased in Cd treated
animals when compared with control groups (CT and LOS
treated rats) (p < 0.05). Kim-1 was evaluated as an early
biomarker of proximal tubule injury showing a clear ex-
pression only in rat kidneys of the Cd group (Figure 3). The
co-administration with LOS reduced Kim-1 expression and
decreased the microalbuminuria when it was compared to
Cd treated rats (Cd vs. Cd + LOS; p < 0.05), indicating a
possible relationship between the impaired endocytosis and
injury induced by Cd and the blockade of AT1 receptor
with LOS.
Effect of Cd on kidney oxidative stress
Increased oxidative stress has been demonstrated to be
involved in Cd toxicity and a possible relationship with
proteinuria has been reported. To evaluate the redox
status in the exposed animals, we measured malondial-
dehyde and 4-hydroxynonenal content in renal cortex
(both used as markers of lipid peroxidation) (Table 3).
No changes were found in lipid peroxidation in the four
different treated groups. In order to explore the produc-
tion of a specific reactive oxygen specie (ROS), wemeasured superoxide (O2
•
¯) production by assessing
NAD(P)H oxidase activity, since it has been reported that
the overactivation of this enzyme constitutes a major
source of oxidative stress in the kidney [40]. Also, it has
been documented that NAD(P)H oxidase is activated via
Ang II through the AT1 receptor [41]. On Table 3, it can
be observed that the rats treated with Cd + LOS showed a
significantly decrease activity of NAD(P)H oxidase com-
pared to the CT group (P < 0.05). Based on the above-
described results, it was concluded that under our
experimental conditions Cd-treatment at 8 weeks did not
induce oxidative stress imbalance.
Effect of Cd on megalin expression
Studies have demonstrated that megalin and cubilin
receptors internalize albumin and LWP in tubular prox-
imal cells [25]. To further determine whether megalin
and cubilin could be involved in the decreased endo-
cytosis (suggested by microalbuminuria observed in Cd-
treated rats); it was investigated whether Cd-treatment
affected the localization and expression of megalin and
cubilin by using confocal microscopy (Figure 4A and
Figure 5A). The quantification of the fluorescence inten-
sity was also evaluated (Figure 4B and Figure 5B).
As shown in Figure 4A, megalin label was observed in
the apical membrane of epithelial proximal cells in the
four different groups and no changes were found along
the experimental groups. Consistently the quantification
of fluorescence intensity showed no changes in the
different groups (Figure 4B). Furthermore, Cd, LOS or
Cd + LOS treatments did not affect mRNA levels of
megalin (Figure 4C). On the other hand, cubilin label,
localized in the apical membrane of epithelial proximal
cells was decreased in the Cd exposed group (Figure 5A)
as confirmed by the quantification of fluorescence inten-
sity showing statistically significant differences in the Cd
group compared with the others groups (Figure 5B). Inter-
estingly mRNA levels of cubilin were not modified by Cd
exposure (Figure 5C). These findings suggest that cubilin
might be participating in the increased microalbuminuria
observed in the Cd-group whereas megalin might not.
Effect of Cd on AT1 receptor expression
Since LOS (an AT1 receptor antagonist) treatment de-
creased the impaired endocytosis induced by Cd, it was
decided to analyse the expression levels of AT1 in the
different treated groups. As it can be seen in Figure 6,
no changes were found in protein levels of AT1 receptor
in the four groups studied (Figure 6A and B).
Discussion
Kidney is the main target organ of Cd exposure. Chronic
exposure to low levels of Cd produces urinary waste
of LWP, suggesting an alteration of endocytosis in the
Figure 1 Effect of subchronic exposure to cadmium on renal
function parameters. Urinary flow rate (A), increased in cadmium+
losartan (Cd + LOS) group compared to control (CT), losartan (LOS), and
cadmium (Cd) groups. Plasma creatinine (B), and creatinine clearance
(C) did not change in the all experimental groups studied. Data are
means ± SEM, n = 9–10 rats per group. aP < 0.05 vs CT, bP < 0.05 vs LOS,
cP < 0.05 vs Cd. Urinary flow rate was analyzed with one way ANOVA
and Bonferroni’s multiple comparison test; plasma creatinine and
creatinine clearance were analyzed with Kruskal-Wallis and Dunn’s
multiple comparison test.
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Cd-induced proteinuria is not fully understood. In normal
physiological conditions, LWP can be filtered through the
glomerulus, but they are reabsorbed by endocytosis in the
proximal tubule. The megalin-cubilin complex is respon-
sible for the endocytosis of proteins in the renal proximal
tubule [25]. On the other hand, it has been observed that
the use of RAS inhibitors prevents proteinuria in diabetic
patients and rats [29-31,42]. Therefore, the aim of this
study was to evaluate the role of megalin-cubilin complex
and AT1 receptor on impaired tubular endocytosis of al-
bumin during a subchronic exposure to Cd. In this study,
we decided to administrate Cd by gavage, for two main
reasons: 1) to control the administered dose, and 2) oral
route reflects the dietary exposure that is the most frequent
route in the non-smoking population [4-6]. To better assess
cellular mechanisms involved in Cd-nephrotoxicity, we de-
cided to use a low dose that would not induce extensive
damage in proximal tubules. Herein, the treatment with
3 mg Cd/kg/day by gavage induced microalbuminuria. This
effect was counteracted by treatment with LOS, which sug-
gests the involvement of AngII and AT1 receptor in
microalbuminuria induced by Cd. Chronic exposure to Cd
induced proteinuria; this effect has been observed in occu-
pationally exposed populations [7,43,44] and experimental
studies have tried to elucidate the mechanism of Cd in-
duced decrease in protein endocytosis. Choi et al. (1999)
observed that in Opossum Kidney epithelial (OK) cells,
endocytosis of albumin was inhibited by exposure to Cd,
but this effect was independent from substrate affinity or
direct interaction of Cd on the endocytic receptor [16]. The
albumin endocytosis occurs via a receptor-mediated mech-
anism. In the proximal tubule, there are two principal
endocytic receptors: megalin and cubilin. Megalin is a large
protein ≈ 600 kDa, and it is a receptor constitutively con-
centrated in proximal tubular brush-border, coated pits,
and vesicles. This receptor has a cytoplasmic tail that con-
tains an internalization motif (two NPXY and a NPXY-like);
which mediates binding to adapter proteins and the forma-
tion of the endocytic vesicle (internalization mediated by
clathrin) [20,45]. Cubilin is a peripheral membrane glyco-
protein (≈460 kDa), without transmembrane and intracellu-
lar domains, and is co-expressed with megalin in the
proximal tubule. Cubilin also binds to proteins such as
Figure 2 Effects of subchronic exposure to cadmium on
markers of proximal tubule damage. Urinary glucose (A),
N-acetyl-β-D-glucosaminidase (NAG) (B), and microalbuminuria (C)
in control (CT), losartan (LOS), cadmium (Cd) and cadmium +
losartan (Cd + LOS) groups. Co-treatment with LOS (Cd + LOS group)
decreased microalbuminuria induced by cadmium (Cd group).
Urinary glucose (A) and NAG (B) did not change in the all
experimental groups. Data are means ± SEM. n = 9–10 rats per
group. aP < 0.05 vs CT, bP < 0.05 vs LOS, dP < 0.05 vs Cd + LOS.
Urinary glucose and microalbuminuria were analyzed with one way
ANOVA and Bonferroni’s multiple comparison tests; urinary NAG was
analyzed with Kruskal-Wallis and Dunn’s multiple comparison tests.
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tion [26]. However, cubilin needs to bind megalin to be in-
ternalized. Although, cubilin also binds amnionless (AMN);
a protein that colocalizes with it, and is important for the
traffic of cubilin to the apical membrane [25]. Moreover,
proteinuria induced by Cd exposure could be due to a) a
decreased expression of membrane receptors involved in
endocytosis, or b) inhibition of endocytosis via the alter-
ation of one of the stages of this mechanism (internaliza-
tion, vesicle recycling, or acidification of endo/lysosomes).
Gena et al. (2010) observed that Cd exposure decreased
megalin expression in Lilly Laboratory Cell Porcine Kidney
cells (LLC-PK1) which was associated with impaired albu-
min endocytosis [14]. In our study, we analyzed the expres-
sion of both, protein and mRNA levels of megalin. In
contrast with previous studies, no changes were observed
in mRNA and protein levels of megalin in Cd-treated rats.
Interestingly, expression of cubilin was decreased by Cd ex-
posure without changes in mRNA levels; suggesting that
Cd might induce a post-transcriptional modification of
cubilin. After albumin filtration, this protein is reabsorbed
along proximal tubule cells by endocytosis. Cubilin hasFigure 3 Effect of subchronic exposure to cadmium on Kim-1
protein expression. Representative confocal images of: Kim-1 with
dipeptidyl peptidase 4 (DppD), as tubule proximal marker. No
expression of Kim-1 was observed in the control (CT), losartan (LOS),
and cadmium + losartan (Cd + LOS) groups, it was observed only in
the cadmium group (Cd). n = 3 rats per group.
Table 3 Effect of subchronic exposure to cadmium on
lipid peroxidation and NAD(P)H oxidase activity




2.58 ± 0.42 1.26 ± 0.39 1.52 ± 0.26 2.08 ± 0.38
NAD(P)H oxidase
activity (FU/mg)
8005 ± 962 5972 ± 1560 5415 ± 1493 3707 ± 577a
LOS, losartan; MDA, malondialdehyde; 4-HNE, hydroxynonenal; FU, fluorescence
unit. Data represent the means ± SEM. n = 5. aP < 0.05 vs CT.
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min reabsorption [26,46]. In our study, microalbuminuria
induced by Cd was attenuated with LOS, also cubilin levels
were recovered in LOS-treated rats, indicating a possible
relationship between cubilin receptor decrease and microal-
buminuria. This data is in agreement with the findings
reported by Oroszlán et al. (2010), where the treatment
with ramipril (an ACE inhibitor) and LOS prevented
downregulation of megalin and cubilin receptors induced
by proliferation signal inhibitors (PSIs) [47]. Increased urin-
ary albumin can be due to two factors: increased glomeru-
lar filtration rate and/or a decreased tubular reabsorption.
In our model, glomerular function was evaluated by meas-
uring plasma creatinine and creatinine clearance. No
changes were found in both parameters evaluated in the
four groups studied. Thus, glomerular function was notFigure 4 Effect of subchronic exposure to cadmium on megalin’s mR
losartan (LOS), cadmium (Cd) and cadmium + losartan (Cd + LOS) groups c
micrographs (A). Quantification of fluorescence intensity is shown in panel
groups (C). Data are expressed as LN mRNA of means ± SEM, n = 3-10 rats
way ANOVA and Bonferroni’s multiple comparison tests.apparently affected after Cd exposure. In addition, urinary
levels of glucose and NAG were unchanged by exposure to
Cd, suggesting the absence of severe proximal tubule dam-
age. However, Kim-1 expression was increased after Cd ex-
posure evidencing a tubular injury, which is consistent with
the observations made by Prozialeck et al. (2007) where
Kim-1 was proposed as an early biomarker of Cd nephro-
toxicity [48]. In this study, LOS administration decreased
Kim-1 expression and microalbuminuria induced by Cd.
In addition to megalin and cubilin receptors; endocyto-
sis involves multiple cellular components such as the en-
dosome. The endosome needs some other molecular
components for its optimal acidification: Na+/H + exchan-
ger (NHE3), vacuolar proton–ATPase (v-H + −ATPase),
and chloride channel 5 (ClC5) [45]. Absence of ClC5 is re-
lated to a dysfunctional endosomal acidification and there-
fore alterations in the reabsorption and the endocytosis,
leading to a renal tubular disorder called Dent’s disease. In
an in vitro model, LLC-PK1 cells incubated with 10 μM of
Cd, ClC5 expression was decreased after 3 h of exposure
[14]. In in vivo models, some authors have observed that
Cd exposure inhibits both v-H+-ATPase [49] and NHE3
[50]. However, in these studies, rats received daily sub-
cutaneous injections of Cd (2 mg Cd/kg/day, 14 days or
3 weeks, respectively) reaching Cd concentrations in the
kidney from 156 to 265 μg/g wet tissue. It is possible thatNA and protein expression. Megalin expression did not change in
ompared to control group (CT), as observed by immunofluorescence
(B). mRNA levels of megalin did not change in the four experimental
per group. Fluorescence intensity and mRNA were analyzed with one
Figure 5 Effect of subchronic exposure to cadmium on cubilin’s mRNA and protein expression. Cubilin expression did not change in
losartan (LOS), and cadmium + losartan (Cd + LOS) groups compared to control group (CT), but was decreased in cadmium (Cd) group as
observed by immunofluorescence micrographs (A). Quantification of fluorescence intensity is shown in panel (B). mRNA levels of cubilin did not
change in the four experimental groups (C). Data are expressed as LN mRNA of means or fluorescence intensity ± SEM, n = 3-10 rats per group.
Statistical analysis was performed with Kruskal-Wallis and Dunn’s multiple comparison tests for fluorescence intensity, and one way ANOVA and
Bonferroni’s multiple comparison tests for mRNA levels.
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lar damage, due to, in both experiments, urinary flow and
total protein excretion increased after Cd exposure.
To explore the mechanism of Cd toxicity, we evalu-
ated oxidative stress by assessing lipid peroxidation. In
our model, we did not observe changes on lipid peroxi-
dation in any the groups studied. However, Wang et al.
(2009) reported, that one of the mechanisms by which
Cd induced nephrotoxicity is by reactive oxygen species
(ROS) overproduction, inferred from the use of an anti-
oxidant agent (N-acetyl cysteine) that protected against
Cd-induced proteinuria [51]. Many other studies indicate
that Cd promotes oxidative stress imbalance [52-54]. It ispossible that we have not detected oxidative stress injury;
may be due to the low amount of Cd and length of expos-
ure (3 mg/kg/day for 8 weeks). Absorption of Cd on
gastrointestinal tract is low (≈5-10%), in our model, a low
concentration of Cd reached the kidneys (7.6 μg/g wet
tissue), and it is possible that renal cells were still able to
respond adequately to the oxidative insult. Thijssen et al.
(2007) report that Cd exposure may trigger a biphasic
defense response in the kidney, and could lead to adapta-
tion and survival [55] maybe by induction of Nuclear fac-
tor erythroid 2 related factor 2 (Nrf2), this transcription
factor binds to antioxidant response elements and regu-
lates the expression of antioxidant genes [56]. On the
Figure 6 Effect of subchronic exposure to cadmium on
angiotensin II type 1 (AT1) receptor expression. AT1 receptor
expression did not change in losartan (LOS), cadmium (Cd) and
cadmium + losartan (Cd + LOS) groups compared to control group
(CT), (A). Densitometry is shown in panel B. Representative image of
one of three independent experiments is shown (A). Relative band
intensity was normalized with actin level (B). Data are means ± SEM,
n = 3. Statistical analysis was performed with Kruskal-Wallis and
Dunn’s multiple comparison tests.
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http://www.biomedcentral.com/1471-2369/14/211other hand, it has been suggested that Cd at low concen-
trations could modulate and inhibit NAD(P)H oxidase
activity [57]. It has been reported that this enzyme is the
one of the major sources of ROS in the kidney [40,58]. It
is known that Ang II increases NAD(P)H oxidase activity
through AT1 receptor [41]. We found a decreased NAD
(P)H oxidase activity in the group treated with Cd + LOS.
In our model, we did not find an increase in oxidative
stress, probably due to an antioxidant response of cell.
The mechanism by which Cd decreases cubilin is still
unclear. To explore this mechanism, we used LOS, an
AT1 receptor antagonist, because endocytosis is regulated
by many factors and amongst them Ang II appears to be
one of them [32,59]. Moreover, other studies showed that
Cd stimulates RAS [33-35] and the use of inhibitors has
shown a protective effect on Cd toxicity [60,61]. Regarding
endocytosis, Ang II acts on two receptors, AT1 and AT2,
both are expressed in proximal tubular cells, and as well
as components of RAS; and it has been observed that, in
diabetic models, the use of RAS inhibitors (ACE inhibitors
and Ang II type 1 receptor) restored the expression of
megalin and in consequence albumin reabsorption
[31,62]. In vitro models have shown that Ang II modulates
albumin endocytosis via AT2-Protein Kinase B (PKB) acti-
vation [59]. Interestingly, Ang II through AT2 may regu-
late cubilin receptor and restore albumin endocytosis [47].Conclusion
In conclusion, LOS treatment decreased the microalbu-
minuria induced by Cd by a mechanism independent of
megalin, and probably dependent on cubilin, at least at
this duration of exposure. Further experiments are re-
quired to determine the mechanism by which Cd regu-
lates cubilin expression.
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